^
Association details:
| Biomarker: | IL2RA expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | camidanlumab tesirine (ADCT-301) (DNA replication inhibitor, CD25-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1178Â Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
Published date:
11/04/2020
Excerpt:
In conclusion, the combination of camidanlumab tesirine and gemcitabine was synergistic both in vitro and in vivo in lymphoma preclinical models. Synergistic anti-tumor activity was also demonstrated in a colorectal cancer model using CD25-ADC, a mouse-cross-reactive version of camidanlumab tesirine, in combination with gemcitabine. Altogether, these novel pre-clinical data warrant translation of the combination between camidanlumab tesirine and gemcitabine into the clinic.
Secondary therapy:
gemcitabine
